Regression of chronic hypoxic pulmonary hypertension by simvastatin
Open Access
- 1 May 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (5), L1105-L1110
- https://doi.org/10.1152/ajplung.00411.2006
Abstract
The 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor, simvastatin, has been shown to attenuate chronic hypoxic pulmonary hypertension (CHPH). Here, we assess whether simvastatin is capable of inducing regression of established CHPH and explore potential mechanisms of statin effect. Rats ( n = 8 in each group) were exposed to chronic hypoxia (10% FiO2) for 2 or 4 wk. Simvastatin treatment (20 mg·kg−1·day−1) commenced after 2 wk of hypoxia, at which time CHPH was fully established, reduced mean pulmonary artery pressure (19 ± 0.5 vs. 27 ± 0.9 mmHg; P < 0.001), the ratio of right ventricular free wall to left ventricular plus septal weight (0.41 ± 0.03 vs. 0.54 ± 0.03; P < 0.001), and medial thickening of small pulmonary arteries (13 ± 0.4 vs. 16 ± 0.4%; P < 0.01) compared with 4-wk hypoxic controls. Supplementation with mevalonate (50 mg·kg−1·day−1) prevented the attenuation of CHPH induced by simvastatin during 2 wk of hypoxia. Because statins are known to inhibit Rho-kinase (ROCK), we determined expression of ROCK-1 and -2 in whole lung by Western blot and ROCK activity by phosphorylation of the myosin-binding subunit of myosin phosphatase. Expression of both ROCK-1 and -2 were markedly diminished in simvastatin-treated animals during normoxia and hypoxia (2- and 4-wk) exposure ( P < 0.01). ROCK activity was increased threefold under hypoxic conditions and normalized with simvastatin treatment ( P < 0.001). We conclude that simvastatin attenuates and induces regression of established CHPH through inhibition of HMG-CoA reductase. Inhibition of ROCK expression and activity may be an important mechanism of statin effect.Keywords
This publication has 25 references indexed in Scilit:
- The Rac and Rho Hall of FameCirculation Research, 2006
- Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertensionBritish Journal of Pharmacology, 2005
- Inhibition of Rho-Kinase Attenuates Hypoxia-Induced Angiogenesis in the Pulmonary CirculationCirculation Research, 2005
- Chronic hypoxia augments protein kinase G-mediated Ca2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signalingAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinaseAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cellsJournal of Molecular and Cellular Cardiology, 2004
- Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in RatsCirculation Research, 2004
- Attenuation of chronic hypoxic pulmonary hypertension by simvastatinAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Pharmacology of competitive inhibitors of HMg-CoA reductasePharmacological Research, 1995